US-based biopharmaceutical company PTC Therapeutics Inc (NASDAQ:PTCT) revealed on Wednesday that it has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for USD150m.
The PRV was granted by the US Food and Drug Administration (FDA) following approval of KEBILIDI (eladocagene exuparvovec-tneq) for the treatment of aromatic l-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder. The sale of the PRV is subject to customary closing conditions.
The PRV program encourages the development of new drugs and biologics for rare pediatric diseases. A PRV can be redeemed to receive priority review of a subsequent marketing application for a different product, or it can be sold or transferred.
European Commission approves Sobi's Aspaveli for rare kidney diseases
US FDA accepts IND application for AskBio's AB-1009
EspeRare and n-Lorem partner to expand European access to ASO therapies for rare genetic diseases
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
argenx secures FDA priority review for VYVGART in seronegative myasthenia gravis
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz